Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Continuous Dialysis Technique Associated With Adsorption Capacity Membranes in Patients With Sepsis Associated - Acute Kidney Injury.
Brief Summary: Septic patients with acute kidney injury (SA-AKI) requiring continuous renal replacement therapies (CRRT) present high mortality due to systemic inflammatory response, cytokine liberation, and finally multiorgan dysfunction. Cytokine plasmatic elimination with continuous venovenous hemofiltration (CVVH) presents frequent complications, known as "dialytrauma", and a high resource cost both technical and human. The study primary end-point is to demonstrate a longer filter life with the use of continuous venovenous hemodialysis (CVVHD) respect to CVVH, both modalities employing the same adsorption capacity membrane. As secondary end-points investigators will try to demonstrate less dialytrauma events of CVVHD respect to CVVH. In order to achieve these objectives investigators have designed a proof of concept exploratory trial that will include those patients whom present SA-AKI meeting CRRT initiation criteria. During the first 72 hours investigators will measure plasmatic elimination capacity of main cytokines, and other clinical and prognostic relevant molecules. Investigators will also measure hemodynamic, respiratory, and metabolic parameters. Adverse effects related to CRRT ("dialytrauma") will also be registrated. Finally, investigators will analyze 90 days survival. Demonstration of a minor complication rate (longer filter patency with less dialytrauma events) with a similar immunomodulating capacity and with its consequent lower cost, should settle the based evidence principles that recommend the use of CVVHD asociated to an adsorption capacity membrane in patients with SA-AKI whom need CRRT.


Options:
A: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
B: Arm Label: CVVHD-ST150; Type: EXPERIMENTAL; Interventions: Other: CVVHD | Arm Label: CVVH-ST150; Type: ACTIVE_COMPARATOR; Interventions: Other: CVVH | Intervention Type: OTHER; Name: CVVHD; Assigned to Arm(s): CVVHD-ST150 | Intervention Type: OTHER; Name: CVVH; Assigned to Arm(s): CVVH-ST150
C: Arm Label: Prismocitrate 18; Type: EXPERIMENTAL; Interventions: Drug: Prismocitrate 18 | Arm Label: No Regional Anticoagulation of CRRT Circuit; Type: ACTIVE_COMPARATOR; Interventions: Other: No Anticoagulation | Intervention Type: DRUG; Name: Prismocitrate 18; Assigned to Arm(s): Prismocitrate 18 | Intervention Type: OTHER; Name: No Anticoagulation; Assigned to Arm(s): No Regional Anticoagulation of CRRT Circuit
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous venvenous hemofiltration (CVVH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous venovenous hemodialysis (CVVHD) | Intervention Type: DEVICE; Name: Continuous venvenous hemofiltration (CVVH); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Continuous venovenous hemodialysis (CVVHD); Assigned to Arm(s): 2

Answer: B